Evidence map›Paper›PMID 39433930›Full record

Trial reportScientific reports2024

Study on bioequivalence and influence of obesity-related indicators on pharmacokinetics and pharmacodynamics for insulin degludec in healthy subjects.

Rui Su, Lei Wan, Yi Tao, Mingxue Zhu, Junliang Pu, Zhongping Li, Yuan Chen, Chengyong Tang

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rui Su *Phase I Clinical Trial Center, Bishan hospital of Chongqing medical university, Chongqing, 402760, China.
Lei Wan *Phase I Clinical Trial Center, Bishan hospital of Chongqing medical university, Chongqing, 402760, China.
Yi TaoOffice of academic research, the First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Mingxue ZhuPhase I Clinical Trial Center, Bishan hospital of Chongqing medical university, Chongqing, 402760, China.
Junliang PuPhase I Clinical Trial Center, Bishan hospital of Chongqing medical university, Chongqing, 402760, China.
Zhongping LiPhase I Clinical Trial Center, Bishan hospital of Chongqing medical university, Chongqing, 402760, China.
Yuan ChenPhase I Clinical Trial Center, Bishan hospital of Chongqing medical university, Chongqing, 402760, China.
Chengyong TangPhase I Clinical Trial Center, Bishan hospital of Chongqing medical university, Chongqing, 402760, China. tcyongwzj@163.com.

Funding

Municipal Postgraduate Joint Training Base of Chongqing Medical University No. lpjd202306the Natural Science Foundation of Chongqing，China No. CSTB2023NSCQ-LZX0019the Scientific Research and Innovation Team Program of Bishan Hospital of Chongqing Medical University No. BYKY-CX2023003the Senior Medical Talents Program of Chongqing for Young and Middle-aged No. 2020GDRC017the Special Research Program for Graduate Student Supervisors of Bishan Hospital of Chongqing Medical University No. BYKY-DS2023010
6 · The paper itself

Abstract

This study aimed to evaluate the bioequivalence between test and reference insulin degludec (IDeg) and the effects of body composition on pharmacokinetics and pharmacodynamics of IDeg in Chinese healthy volunteers. In this randomized, open-label, crossover trial, 30 healthy Chinese males were assigned to receive a single subcutaneous dose (0.4 IU/kg) of each formulation under 24-h euglycemic hyperinsulinaemic clamp. Body compositions were analysed prior to administration and blood samples were collected at specific times. The 90% of primary pharmacokinetic parameters and 95% of primary pharmacodynamic parameters confidence intervals for the ratio of the least-squares geometric means were all in the range of 80-125%. As the fat content level increases, C

Indexed as

Cross-Over StudiesHealthy VolunteersHypoglycemic AgentsInsulin, Long-ActingObesityTherapeutic EquivalencyAdultArea Under CurveBlood GlucoseBody CompositionGlucose Clamp TechniqueHumansMaleYoung AdultBlood GlucoseHypoglycemic Agentsinsulin degludecInsulin, Long-ActingBioequivalenceInsulin degludecObesityPharmacodynamicsPharmacokinetics

Identifiers

PMID39433930
PMCPMC11494130

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.